Omnicell $172.5 million convertible senior notes offering
The convertible senior notes are due 2029
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
McKesson $2.49 billion acquisition of controlling interest in Core Ventures
We are advising McKesson on the transaction
Recursion Pharmaceuticals $230 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
RxSight $115 million follow-on offering
The stock is listed on the Nasdaq Global Market
Alector $125 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
Natera $250 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $300 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
RxSight $50 million follow-on offering
The stock is listed on the Nasdaq Global Market
Coherus BioSciences $150 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Natera $400 million follow-on offering
The shares are listed on Nasdaq